Skip to main content
Download PDF

Correction to: Treatment duration with immune-based therapies in Cancer: an enigma

Journal for ImmunoTherapy of Cancer volume 7, Article number: 56 (2019) Cite this article

The Original Article was published on 05 December 2018

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:143

Doi: 10.1186/s40425-018-0465-0

Following publication of the original article [1], the authors reported an error in the typesetting of their article. The first section of the main text was mistakenly included in the abstract. This section begins with the sentence “Chemotherapy and immune-based therapies provide antitumor effects through completely different mechanisms” and ends with the following sentence:

“In exploring treatment duration with immune based therapies, we need to answer the following: (1) does indefinite treatment with immune based therapies exhaust the immune system counteracting its own mechanism of action leading to tumor progression and (2) how can clinical trials be designed to identify the optimal duration of immunebased therapy that prevents immune cell exhaustion but supports anti-tumor immunity.”

The published apologizes for any inconvenience caused by this error.

Reference

  1. Bantia and Choradia. Journal for ImmunoTherapy of Cancer. 2018;6:143. https://doi.org/10.1186/s40425-018-0465-0.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nitor Therapeutics, 689, Highland Lakes Cove, Birmingham, AL-35242, USA

    Shanta Bantia

  2. Palo Alto Veterans Affairs Hospital, 3801 Miranda Ave, Palo Alto, CA, 94304, USA

    Nirmal Choradia

Authors
  1. Shanta Bantia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nirmal Choradia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shanta Bantia.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bantia, S., Choradia, N. Correction to: Treatment duration with immune-based therapies in Cancer: an enigma. j. immunotherapy cancer 7, 56 (2019). https://doi.org/10.1186/s40425-018-0486-8

Download citation

  • Received:

  • Published:

  • DOI: https://doi.org/10.1186/s40425-018-0486-8